B. Metzler seel. Sohn & Co. AG Sells 159,019 Shares of Danaher Corporation $DHR

Key Points

• B. Metzler seel. Sohn & Co. AG reduced its holdings in Danaher Corporation by 62.8%, selling 159,019 shares during the first quarter.
• In a recent transaction, Director Teri List sold 2,778 shares of Danaher stock, leading to an 11.81% decrease in her position.
• Danaher reported a quarterly earnings per share of $1.80, exceeding estimates, with revenues of $5.94 billion, reflecting a year-over-year growth of 3.4%.

B. Metzler seel. Sohn & Co. AG lessened its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 62.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 94,100 shares of the conglomerate's stock after selling 159,019 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Danaher were worth $19,290,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Heck Capital Advisors LLC bought a new stake in shares of Danaher during the 4th quarter valued at $27,000. GHP Investment Advisors Inc. boosted its holdings in shares of Danaher by 396.0% during the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after buying an additional 99 shares in the last quarter. Sierra Ocean LLC boosted its holdings in shares of Danaher by 116.9% during the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after buying an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC bought a new stake in shares of Danaher during the 1st quarter valued at $31,000. Finally, Dunhill Financial LLC boosted its holdings in shares of Danaher by 68.4% during the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after buying an additional 67 shares in the last quarter. Institutional investors own 79.05% of the company's stock.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 11.20% of the stock is owned by insiders.

Danaher Trading Down 0.6%

Danaher stock opened at $206.47 on Wednesday. The firm has a 50 day moving average of $201.02 and a 200 day moving average of $199.43. The firm has a market capitalization of $147.84 billion, a price-to-earnings ratio of 43.93, a P/E/G ratio of 2.90 and a beta of 0.73. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.90. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm's quarterly revenue was up 3.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Wells Fargo & Company dropped their price target on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Guggenheim reiterated a "buy" rating and issued a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Finally, Evercore ISI decreased their target price on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Seventeen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $247.61.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.